Orion Oyj

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FI0009014377
EUR
60.85
17.31 (39.75%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

230.27 k

Shareholding (Mar 2024)

FII

0.04%

Held by 2 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 6,650 Million ()

stock-summary
P/E

19.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.15

stock-summary
Return on Equity

30.73%

stock-summary
Price to Book

6.53

Revenue and Profits:
Net Sales:
417 Million
(Quarterly Results - Jun 2025)
Net Profit:
82 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.19%
0%
25.19%
6 Months
30.91%
0%
30.91%
1 Year
67.26%
0%
67.26%
2 Years
72.04%
0%
72.04%
3 Years
32.74%
0%
32.74%
4 Years
74.66%
0%
74.66%
5 Years
72.87%
0%
72.87%

Orion Oyj for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.23%
EBIT Growth (5y)
5.61%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
1.24
Tax Ratio
20.16%
Dividend Payout Ratio
69.83%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
40.73%
ROE (avg)
29.77%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
7.94
EV to EBIT
15.92
EV to EBITDA
13.23
EV to Capital Employed
7.06
EV to Sales
4.43
PEG Ratio
0.24
Dividend Yield
NA
ROCE (Latest)
44.33%
ROE (Latest)
41.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 17.34% vs -18.23% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 34.58% vs -16.49% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "416.80",
          "val2": "355.20",
          "chgp": "17.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "116.90",
          "val2": "90.80",
          "chgp": "28.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.00",
          "chgp": "20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "82.50",
          "val2": "61.30",
          "chgp": "34.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "246.90%",
          "val2": "217.10%",
          "chgp": "2.98%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 29.39% vs -10.65% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.17% vs -37.97% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,541.40",
          "val2": "1,191.30",
          "chgp": "29.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "498.70",
          "val2": "284.60",
          "chgp": "75.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.40",
          "val2": "5.70",
          "chgp": "47.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-38.00",
          "val2": "29.70",
          "chgp": "-227.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "329.90",
          "val2": "216.80",
          "chgp": "52.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "290.20%",
          "val2": "196.40%",
          "chgp": "9.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
416.80
355.20
17.34%
Operating Profit (PBDIT) excl Other Income
116.90
90.80
28.74%
Interest
1.20
1.00
20.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
82.50
61.30
34.58%
Operating Profit Margin (Excl OI)
246.90%
217.10%
2.98%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 17.34% vs -18.23% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 34.58% vs -16.49% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,541.40
1,191.30
29.39%
Operating Profit (PBDIT) excl Other Income
498.70
284.60
75.23%
Interest
8.40
5.70
47.37%
Exceptional Items
-38.00
29.70
-227.95%
Consolidate Net Profit
329.90
216.80
52.17%
Operating Profit Margin (Excl OI)
290.20%
196.40%
9.38%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 29.39% vs -10.65% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 52.17% vs -37.97% in Dec 2023

stock-summaryCompany CV
About Orion Oyj stock-summary
stock-summary
Orion Oyj
Pharmaceuticals & Biotechnology
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Company Coordinates stock-summary
Company Details
Orionintie 1A , ESPOO None : 02200
stock-summary
Tel: 358 10 4261358 10 4262883
stock-summary
Registrar Details